Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Licenses Clinomics Cancer Database

NEW YORK, March 30 (GenomeWeb News) - Clinomics has licensed its Oncology Cell Signalling Database to AstraZeneca, the company's parent, Cytomyx holdings, said today.

 

The searchable database includes over 30,000 tissue samples from different forms of human cancer, and protein expression of 100 cell signaling proteins across all of these samples, the company said. It allows companies to biologically characterize gene and protein targets in numerous diseases, through searching numerous data fields including medical history, pathology, demographics, and treatment outcomes.

 

Under the non-exclusive agreement, AstrZeneca has obtained multiple user licenses to the database.

 

Cytomyx, of Cambridge, UK, acquired Clinomics in December 2003.

The Scan

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.

In the Ice

Cosmos magazine reports that researchers have uncovered more than two dozen ancient viruses in a Tibetan glacier.

Nature Papers Present Method to Uncover Differential RNA Modifications, Neutrophils in Innate Immune Response

In Nature this week: computational approach to identifying differential RNA modifications, and more.